Rapport Therapeutics, Inc. (RAPP) - 2024 Annual Report Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2024. Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders using its proprietary Receptor Associated Protein (RAP) technology platform. The company completed its Initial Public Offering (IPO) in June 2024. Its lead asset, RAP-219, is an AMPA receptor negative allosteric modulator targeting TARP γ8, currently in Phase 2a trials for refractory focal epilepsy.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(78.3) million | $(34.8) million |
| Operating Expenses | $83.1 million | $36.2 million |
| Cash, Cash Equivalents & Short-Term Investments | $305.3 million | $147.5 million |
| Accumulated Deficit | $(123.7) million | $(45.4) million |
| Net Cash Used in Operating Activities | $(64.8) million | $(27.2) million |
Note: The company has no revenue and is not profitable. Margins are not applicable.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss more than doubled from $34.8 million in 2023 to $78.3 million in 2024, driven by a 130% increase in operating expenses.
- R&D Expense Surge: Research and development expenses rose to $60.9 million (from $28.0 million), primarily due to costs associated with the Phase 2a trial in refractory focal epilepsy, start-up costs for the diabetic peripheral neuropathic pain (DPNP) trial, and increased personnel costs.
- Capital Raise: The company raised $157.6 million in net proceeds from its IPO and concurrent private placement in June 2024, significantly bolstering its cash position.
- Interest Income: Interest income increased to $12.1 million (from $2.5 million) due to higher cash balances and interest rates.
Guidance, Outlook, and Risks
Clinical Outlook:
- RAP-219 (Focal Epilepsy): A Phase 2a proof-of-concept trial is ongoing. Topline results are expected in the third quarter of 2025.
- RAP-219 (Bipolar Mania): The company intends to initiate a Phase 2a trial in the third quarter of 2025, with results expected in the first half of 2027.
- RAP-219 (Diabetic Peripheral Neuropathic Pain - DPNP): The FDA placed a clinical hold on the IND for this indication in Q4 2024, requesting additional information on protocol design. This hold does not impact the epilepsy or bipolar trials.
Management believes existing cash, cash equivalents, and short-term investments ($305.3 million) are sufficient to fund operations through the end of 2026.
Key Risks:- Regulatory Delays: The clinical hold on the DPNP trial poses a risk to the timeline for that specific indication.
- Capital Needs: The company expects to continue incurring significant losses and will require additional funding to advance clinical programs and commercialize products.
- Development Uncertainty: As a clinical-stage company, there is no guarantee that product candidates will successfully complete trials or receive regulatory approval.
Investor Verification Checklist
- Verify the status and expected resolution timeline of the FDA clinical hold on the RAP-219 DPNP trial.
- Monitor the enrollment progress and safety data of the ongoing Phase 2a trial in refractory focal epilepsy.
- Review the company's cash burn rate relative to its stated runway through the end of 2026.
- Assess the potential impact of the Janssen Pharmaceutical license agreement, which includes up to $76 million in development milestones and royalties.
- Confirm the timeline for the initiation of the bipolar mania Phase 2a trial.